95.03
0.89 (0.95%)
| Previous Close | 94.14 |
| Open | 94.70 |
| Volume | 668,803 |
| Avg. Volume (3M) | 1,034,560 |
| Market Cap | 22,850,482,176 |
| Price / Earnings (Forward) | 7.04 |
| Price / Sales | 6.13 |
| Price / Book | 1.05 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2025 |
| Profit Margin | -27.89% |
| Operating Margin (TTM) | -270.46% |
| Diluted EPS (TTM) | -3.72 |
| Quarterly Revenue Growth (YOY) | -2.60% |
| Quarterly Earnings Growth (YOY) | -43.30% |
| Total Debt/Equity (MRQ) | 1.55% |
| Current Ratio (MRQ) | 10.18 |
| Operating Cash Flow (TTM) | -255.70 M |
| Levered Free Cash Flow (TTM) | -335.98 M |
| Return on Assets (TTM) | -3.67% |
| Return on Equity (TTM) | -3.94% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | BioNTech SE | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 3.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 1.63 |
|
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 62.69% |
| % Held by Institutions | 22.24% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Flossbach Von Storch Se | 30 Sep 2025 | 4,230,033 |
| Dodge & Cox | 30 Sep 2025 | 3,647,091 |
| Temasek Holdings (Private) Ltd | 30 Sep 2025 | 1,506,027 |
| Candriam S.C.A. | 30 Sep 2025 | 589,452 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 140.00 (HC Wainwright & Co., 47.32%) | Buy |
| Median | 125.50 (32.06%) | |
| Low | 117.00 (UBS, 23.12%) | Hold |
| Average | 127.00 (33.64%) | |
| Total | 2 Buy, 2 Hold | |
| Avg. Price @ Call | 103.81 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Nov 2025 | 140.00 (47.32%) | Buy | 105.07 |
| UBS | 06 Nov 2025 | 117.00 (23.12%) | Hold | 103.35 |
| JP Morgan | 23 Oct 2025 | 120.00 (26.28%) | Hold | 104.75 |
| Morgan Stanley | 10 Oct 2025 | 131.00 (37.85%) | Buy | 102.06 |
No data within this time range.
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 02 Jun 2022 | - | 17 Jun 2022 | 2.111 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2022 | 2.11 | 1 | 1.41 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |